Your current location:Home > Latest news text

天才冲冲冲

Major Mohit Sharma’s brother reacts after CBFC clears Dhurandhar_我的网站

学校2013

一 |     Aditya Dhar’s Dhurandhar, starring Ranveer Singh, has been cleared for release by the Central Board of Film Certification (CBFC). This has come after a week of legal and emotional scrutiny. The film was initially challenged in the Delhi High Court by the parents of late Major Mohit Sharma. He was a decorated Army officer. The film was at the centre of controversy after online chatter suggested the storyline mirrors real-life events. The High Court had directed the CBFC to examine the family’s objections and consult the Indian Army if needed. On Tuesday, the board approved the film, categorising it as a fictional work.     Speaking exclusively to HT City, Major Mohit Sharma’s brother, Madhur Sharma, responded to the development. “I am sure the board followed the required process, and they acted quickly, which is a good thing,” he said. While the family has not been informed of the material the CBFC evaluated, Madhur believes due diligence would have been done. “They’ve called it fiction, so I hope the disclaimer is placed prominently.”                                                                 View this post on Instagram          A post shared by Ranveer Singh (@ranveersingh)               However, he feels one key step was missed. “A screening for the parents could have been arranged,” he said. “It would have helped clear any social media misconceptions. People who lived with him are better positioned to recognise if any part resembles his life.”     As social media intensified comparisons between Ranveer Singh’s character and the late officer following the trailer launch, Madhur himself had posted concerns online. He clarified why the family still went ahead with the petition: “There was a 36–48 hour gap between my tweet and Aditya Dhar’s clarification. The petition was filed within that window.”     Madhur maintains the family isn’t seeking compensation or credit, only transparency. “We’re not asking for anything. We just want empathy. If the film is inspired by him, acknowledge it. If not, state clearly that the speculation is incorrect. This is about respecting every family that has lost a soldier.”     The family will consult their legal team before deciding next steps.     Also Read: Photos: Ranveer Singh Uplifts Dhurandhar’s Music Launch With His Electric Energy。    

根据美国疾病控制与预防中心(CDC)近期更新的数据,如今在美传播的主要变体是以KP.2为首的“FLiRT”一族:KP.2的占比已经达到25%。
值得注意的是,新冠病毒的新变种KP.2正在加拿大、英国等多个国家迅速传播。今年5月初,世界卫生组织已将KP.2亚变种列为监测中变异株。世界卫生组织表示,将继续密切监测病毒的演变。
美国疾控中心最新数据显示,目前,KP.2占美国感染病例的四分之一以上。截至5月11日的两周内,KP.2估计占美国病例的28.2%,高于4月中旬的约6%和3月中旬的仅1%。
据悉,KP.2是JN.1变种的后代,有时被称为“FLiRT”变体,因其在刺突蛋白中的突变位置而得名。包括KP.1.1在内的其他FLiRT变种也在美国流行,但还没有KP.2那么普遍。“FLiRT”最初是在美国下水道系统中发现的,但确切来源尚不清楚。
这意味着,新冠病毒仍在变异。CDC发言人发出警告称,病毒通过突变不断发生变化,有时这些突变会导致病毒产生新的变种。一些变化和突变使病毒更容易传播或使其对治疗或疫苗产生抵抗力。随着病毒的传播,它可能会发生变化并且变得更难以阻止。
当前,CDC正在监测KP.2和KP.1.1引起的感染。早期数据表明,它们产生与JN.1相似的症状,通常出现在感染后2至14天,这些症状主要影响上呼吸道,包括喉咙痛、鼻塞、流鼻涕、咳嗽、发烧、头痛以及味觉和嗅觉丧失。

二 |

美国传染病专家罗伯特·墨菲博士表示,虽然症状和严重程度似乎与之前的新冠病毒毒株大致相同,但新变种似乎更具传染性。

三 | 墨菲敦促公众了解新冠疫苗注射的最新情况,特别是那些因该病毒而出现严重并发症的风险较高的人。虽然大多数人对疫苗接种或以前感染过的新冠病毒有一定的免疫力,但墨菲指出,“对于新冠病毒感染(COVID-19),免疫力会随着时间的推移而减弱。

四 | ”

到目前为止,这一变体尚未被证明会导致更严重的疾病,疫苗也仍然有效。
英国华威大学病毒学家、分子肿瘤学教授Lawrence Young表示,“我们担心这个KP.2会在夏天引起一波感染。早期证据表明,KP.2似乎比以前的亚株更具传染性,但现在判断它是否更危险还为时过早。

五 | 我们应该监测这个亚谱系的传播,但鉴于现在没有很多测试,这很困难。”

值得注意的是,新冠病毒的新变体FLiRT正在加拿大、英国等国家迅速传播。

六 |

当地时间5月9日,据Global News报道,KP.2迅速在加拿大占据主导地位,截至4月28日,全国数据显示,KP.2占加拿大所有COVID-19病例的26.6%,超过其他JN.1亚变种。
同时,FLiRT变体在英国似乎也逐渐占据主导地位。

七 | Cov Spectrum的数据表明,KP.2和KP.1.1的组合占英国病例的40%。英国卫生安全局(UKHSA)尚未对FLiRT发表评论,但英国病例的增加可能表明它是新的主要变种。

今年5月初,世界卫生组织(WHO)已将KP.2亚变种列为监测中变异株。世卫组织COVID-19技术负责人Maria Van Kerkhove此前表示,“KP.2是JN.1的后代谱系,而JN.1是全球主要菌株,KP.2刺突蛋白有额外的突变。还有其他新兴变体,JN.1不断发展,我们将继续看到这些变体传播。

八 | ”

不过,截至目前,中国国内尚无该毒株传播的迹象。据中国疾控中心公布的最新数据,2024年4月1日-4月30日,31个省(自治区、直辖市)及新疆生产建设兵团共报送11299例本土病例新冠病毒基因组有效序列,均为奥密克戎变异株。主要流行株为JN.1系列变异株,占比前三位的分别为JN.1、JN.1.4和JN.1.16。
(羊城晚报•羊城派综合红星新闻、财联社、中疾控官网等)

Current article:http://s55y5ka.aiwengchuanzuodahuai.shop/q029o/20260826/498440.html

Published on:05:13:27


Related reading
Copyright © 2020-2099 天才冲冲冲 All Rights Reserved 天才冲冲冲 Copyright